Monopar Therapeutics (MNPR) EPS (Basic) (2017 - 2020)
Monopar Therapeutics (MNPR) has disclosed EPS (Basic) for 4 consecutive years, with -$0.19 as the latest value for Q4 2020.
- Quarterly EPS (Basic) fell 46.15% to -$0.19 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$0.58 through Dec 2020, down 26.09% year-over-year, with the annual reading at $12.7 million for FY2022, 1739045652.07% up from the prior year.
- EPS (Basic) hit -$0.19 in Q4 2020 for Monopar Therapeutics, down from -$0.15 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.04 in Q1 2017 to a low of -$1.68 in Q3 2017.
- Historically, EPS (Basic) has averaged -$0.2 across 4 years, with a median of -$0.1 in 2018.
- Biggest YoY gain for EPS (Basic) was 95.83% in 2018; the steepest drop was 125.0% in 2018.
- Year by year, EPS (Basic) stood at -$0.05 in 2017, then tumbled by 100.0% to -$0.1 in 2018, then crashed by 30.0% to -$0.13 in 2019, then plummeted by 46.15% to -$0.19 in 2020.
- Business Quant data shows EPS (Basic) for MNPR at -$0.19 in Q4 2020, -$0.15 in Q3 2020, and -$0.14 in Q2 2020.